All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Consultant-Needed-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

AiCuris

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

Royalty Pharma Acquires Partial Royalty Interest On Prevymis™ (Letermovir) From Aicuris Anti-Infective Cures Gmbh

Contact the Supplier

Lead Product(s): Letermovir

Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Royalty Pharma

Deal Size: $220.0 million Upfront Cash: $220.0 million

Deal Type: Acquisition June 09, 2020

Details:

Prevymis™ (letermovir) was approved by the US FDA in 2017 and by the EMA and Japan’s PMDA in 2018 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant who are at high risk for CMV reactivation.